A benchmarking study comparing ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV)’s blood test against ultrasound has been published in the scientific journal “Cancers” with positive outcomes. The study found that Cleo’s initial test for the surgical triage market significantly outperforms the current clinical workflows that use Cancer Antigen 125 (CA125) and ultrasound to predict
Read More
In FY24, AI-driven language and content services provider Straker (ASX: STG) faced market conditions tougher than initially expected, with lower revenue growth and subdued M&A activity. Investors did not look kindly upon this underperformance, with Straker shares falling about 37% in FY24. During the period, Straker diversified its services to include a generative AI-based product
Read More
The NSW Government has remained loyal to HR tech company AD1 Holdings (ASX: AD1) by ending their contract for 2-years which will extend use of AD1’s ApplyDirect recruitment software services, specifically for the iWorkforNSW platform. Over the past 12 months, the iWorkforNSW platform has seen substantial activity, with over 60,000 job postings, 970,000 applications, and
Read More
Medical device company PainChek (ASX: PCK), developer of a smartphone-based pain assessment and monitoring application, has been granted a patent in 20 European nations by the European Patent Office (EPO). The patent application is titled “A Pain Assessment Method and System” and allows PainChek to safeguard the intellectual property of its pain assessment and monitoring
Read More
COVID-19 was a turning point for the telehealth industry. In Australia, between 2020 and 2022, more than 100 million telehealth services were delivered to around 17 million Australians. Over $5 billion in Medicare benefits were paid, and about 90,000 medical practitioners have now used telehealth services to support their patients. Aussies have been quick to
Read More
According to TechSci Research report, “Hypersonic Weapons Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Hypersonic Weapons Market stood at USD 8.41 billion in 2022 and is anticipated to grow with a CAGR of 8.23% in the forecast period, 2024-2028 The Global Hypersonic Weapons Market represents a dynamic and strategically significant
Read More
Ischaemia is a condition in which the blood supply to any part of the body is so severely restricted that it receives no oxygen and can result in a stroke. Early detection is crucial, and so, medical devices company EMVision (ASX: EMV) has been conducting multi-site clinical trials to advance its neurodiagnostic AI algorithms to
Read More
Global molecular diagnostics company Genetic Signatures (ASX: GSS) has decided to halt the development of its EasyScreen Essentials Respiratory Detection Kit for the US market due to increased competition and changing market dynamics. It will now focus its effort and investment on the anticipated launch of the EasyScreen Gastrointestinal Parasite Detection Kit in the US.
Read More
PYC Therapeutics (ASX: PYC), a clinical-stage biotechnology company, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its investigational drug candidate, PYC-001. This precision therapy is designed to treat Autosomal Dominant Optic Atrophy (ADOA), a rare and progressive blinding eye disease. This designation is expected
Read More
Winter is coming, and a Game of Thrones-themed game by video game developer PlaySide Studios (ASX: PLY) is being developed with it. The Company has teamed up with Warner Bros. Interactive Entertainment and HBO to develop a multiplayer strategy game based on the Emmy Award- and Golden Globe-winning Game of Thrones series. This new premium
Read More
